Fulranumab: Interim Phase II data

Interim data from the 12-week efficacy stage of an ongoing, 104-week, double-blind Phase II trial in 466 patients with moderate to severe osteoarthritic pain of the hip and knee inadequately controlled with current pain therapy showed that 3 mg subcutaneous

Read the full 400 word article

How to gain access

Continue reading with a
two-week free trial.